Compare Stocks: CCCC, XNCR, TYRA, and VIR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CCCC C4 Therapeutics	$4.24 +3.9%	$3.90	$1.69 ▼ $5.17	$521.65M	2.91	2.72 million shs	3.40 million shs
TYRA Tyra Biosciences	$25.29 +1.1%	$29.78	$9.96 ▼ $40.65	$1.51B	0.77	908,490 shs	420,410 shs
VIR Vir Biotechnology	$9.24 +2.7%	$9.29	$4.25 ▼ $11.66	$1.56B	1.66	2.49 million shs	1.02 million shs
XNCR Xencor	$23.34 +1.5%	$16.56	$7.13 ▼ $23.45	$1.74B	0.85	855,470 shs	443,054 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CCCC C4 Therapeutics	+4.62%	+12.09%	+7.09%	+14.61%	+75.11%
TYRA Tyra Biosciences	-1.11%	-7.20%	-23.91%	-32.45%	+132.74%
VIR Vir Biotechnology	+0.45%	+2.62%	-5.16%	+2.39%	+96.94%
XNCR Xencor	-0.82%	+14.95%	+53.78%	+104.90%	+197.80%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CCCC C4 Therapeutics	$4.24 +3.9%	$3.90	$1.69 ▼ $5.17	$521.65M	2.91	2.72 million shs	3.40 million shs
TYRA Tyra Biosciences	$25.29 +1.1%	$29.78	$9.96 ▼ $40.65	$1.51B	0.77	908,490 shs	420,410 shs
VIR Vir Biotechnology	$9.24 +2.7%	$9.29	$4.25 ▼ $11.66	$1.56B	1.66	2.49 million shs	1.02 million shs
XNCR Xencor	$23.34 +1.5%	$16.56	$7.13 ▼ $23.45	$1.74B	0.85	855,470 shs	443,054 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CCCC C4 Therapeutics	+4.62%	+12.09%	+7.09%	+14.61%	+75.11%
TYRA Tyra Biosciences	-1.11%	-7.20%	-23.91%	-32.45%	+132.74%
VIR Vir Biotechnology	+0.45%	+2.62%	-5.16%	+2.39%	+96.94%
XNCR Xencor	-0.82%	+14.95%	+53.78%	+104.90%	+197.80%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CCCC C4 Therapeutics	2.57	Moderate Buy	$7.75	82.78% Upside
TYRA Tyra Biosciences	2.87	Moderate Buy	$46.90	85.45% Upside
VIR Vir Biotechnology	2.89	Moderate Buy	$20.63	123.21% Upside
XNCR Xencor	2.44	Hold	$24.86	6.50% Upside

Current Analyst Ratings Breakdown

Latest CCCC, XNCR, TYRA, and VIR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/10/2026	VIR Vir Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/6/2026	VIR Vir Biotechnology	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$25.00
8/6/2026	XNCR Xencor	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$19.00 ➝ $20.00
8/6/2026	XNCR Xencor	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$26.00 ➝ $30.00
8/6/2026	XNCR Xencor	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$43.00 ➝ $44.00
8/5/2026	TYRA Tyra Biosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$42.00
7/30/2026	XNCR Xencor	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$26.00
7/17/2026	CCCC C4 Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	TYRA Tyra Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/8/2026	VIR Vir Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/7/2026	XNCR Xencor	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$29.00 ➝ $27.00

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CCCC C4 Therapeutics	$35.95M	14.51	N/A	N/A	$2.65 per share	1.60
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	$5.93 per share	N/A
VIR Vir Biotechnology	$68.56M	22.81	N/A	N/A	$5.81 per share	1.59
XNCR Xencor	$125.58M	13.82	N/A	N/A	$6.77 per share	3.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CCCC C4 Therapeutics	-$104.99M	-$1.19	N/A	N/A	N/A	-289.44%	-47.15%	-31.91%	N/A
TYRA Tyra Biosciences	-$119.95M	-$2.40	N/A	N/A	N/A	N/A	-46.39%	-43.07%	N/A
VIR Vir Biotechnology	-$437.99M	-$1.86	N/A	N/A	N/A	-638.88%	-29.99%	-23.62%	N/A
XNCR Xencor	-$91.92M	-$2.17	N/A	N/A	N/A	-155.59%	-28.66%	-20.38%	N/A

Latest CCCC, XNCR, TYRA, and VIR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	CCCC C4 Therapeutics	-$0.2264	-$0.18	+$0.0464	-$0.18	$4.00 million	$6.64 million
8/5/2026	Q2 2026	VIR Vir Biotechnology	$0.3326	$0.47	+$0.1374	$0.47	$135.88 million	$238.95 million
8/5/2026	Q2 2026	XNCR Xencor	-$0.8015	-$0.29	+$0.5115	-$0.29	$18.89 million	$51.22 million
8/4/2026	Q2 2026	TYRA Tyra Biosciences	-$0.6499	-$0.69	-$0.0401	-$0.69	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CCCC C4 Therapeutics	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CCCC C4 Therapeutics	N/A	9.00	9.00
TYRA Tyra Biosciences	N/A	14.90	14.91
VIR Vir Biotechnology	N/A	6.04	6.04
XNCR Xencor	N/A	6.39	6.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CCCC C4 Therapeutics	78.81%
TYRA Tyra Biosciences	84.14%
VIR Vir Biotechnology	65.32%
XNCR Xencor	N/A

Insider Ownership

Company	Insider Ownership
CCCC C4 Therapeutics	5.60%
TYRA Tyra Biosciences	12.50%
VIR Vir Biotechnology	2.90%
XNCR Xencor	5.08%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CCCC C4 Therapeutics	150	123.03 million	104.38 million	Optionable
TYRA Tyra Biosciences	20	59.68 million	52.22 million	Optionable
VIR Vir Biotechnology	580	169.22 million	164.31 million	Optionable
XNCR Xencor	280	74.35 million	70.58 million	Optionable

CCCC, XNCR, TYRA, and VIR Headlines

Recent News About These Companies

Xencor, Inc. (XNCR) Stock Major Holders - Yahoo Finance

August 12 at 2:36 PM | finance.yahoo.com

Xencor (NASDAQ:XNCR) Hits New 1-Year High - Here's What Happened

August 12 at 4:19 AM | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Xencor (XNCR), Alpha Teknova (TKNO) and Solventum Corporation (SOLV)

August 11 at 10:27 PM | theglobeandmail.com

Xencor (NASDAQ:XNCR) Price Target Raised to $44.00

August 9, 2026 | americanbankingnews.com

Xencor (NASDAQ:XNCR) Sets New 12-Month High on Strong Earnings

August 8, 2026 | americanbankingnews.com

Xencor (NASDAQ:XNCR) Upgraded by Wall Street Zen to Hold Rating

August 8, 2026 | americanbankingnews.com

Xencor (NASDAQ:XNCR) Stock Rating Upgraded by Wall Street Zen

August 8, 2026 | marketbeat.com

Xencor: Q2 Earnings Snapshot

August 7, 2026 | sfgate.com

RBC Capital Sticks to Their Buy Rating for Xencor (XNCR)

August 7, 2026 | theglobeandmail.com

Xencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of "Hold" by Brokerages

August 7, 2026 | americanbankingnews.com

Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Hold" by Brokerages

August 7, 2026 | marketbeat.com

Xencor Reports Second Quarter 2026 Financial Results

August 7, 2026 | aol.comA

Xencor (NASDAQ:XNCR) Price Target Raised to $30.00

August 6, 2026 | marketbeat.com

Xencor (NASDAQ:XNCR) Hits New 52-Week High Following Better-Than-Expected Earnings

August 6, 2026 | marketbeat.com

Xencor (NASDAQ:XNCR) Price Target Raised to $44.00 at Cantor Fitzgerald

August 6, 2026 | marketbeat.com

Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates

August 5, 2026 | zacks.com

Xencor (NASDAQ:XNCR) Releases Earnings Results, Beats Expectations By $0.51 EPS

August 5, 2026 | marketbeat.com

Xencor (NASDAQ:XNCR) Trading Down 3.9% - Here's Why

August 3, 2026 | marketbeat.com

Xencor’s XmAb412 Enters First-in-Human Testing: What Early-Stage Investors Should Watch

August 3, 2026 | tipranks.com

Xencor (NASDAQ:XNCR) Reaches New 1-Year High - Should You Buy?

July 30, 2026 | marketbeat.com

Wedbush Reiterates Outperform Rating for Xencor (NASDAQ:XNCR)

July 30, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCCC, XNCR, TYRA, and VIR Company Descriptions

C4 Therapeutics NASDAQ:CCCC

$4.24 +0.16 (+3.92%)

Closing price 04:00 PM Eastern

Extended Trading

$4.22 -0.02 (-0.45%)

As of 05:55 PM Eastern

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Tyra Biosciences NASDAQ:TYRA

$25.29 +0.27 (+1.08%)

Closing price 04:00 PM Eastern

Extended Trading

$24.60 -0.69 (-2.73%)

As of 05:53 PM Eastern

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Vir Biotechnology NASDAQ:VIR

$9.24 +0.24 (+2.67%)

Closing price 04:00 PM Eastern

Extended Trading

$9.25 +0.01 (+0.11%)

As of 05:54 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Xencor NASDAQ:XNCR

$23.34 +0.35 (+1.52%)

Closing price 04:00 PM Eastern

Extended Trading

$23.34 0.00 (0.00%)

As of 04:45 PM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CCCC, XNCR, TYRA, and VIR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CCCC, XNCR, TYRA, and VIR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CCCC, XNCR, TYRA, and VIR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCCC, XNCR, TYRA, and VIR Company Descriptions

C4 Therapeutics NASDAQ:CCCC

Tyra Biosciences NASDAQ:TYRA

Vir Biotechnology NASDAQ:VIR

Xencor NASDAQ:XNCR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CCCC, XNCR, TYRA, and VIR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CCCC, XNCR, TYRA, and VIR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CCCC, XNCR, TYRA, and VIR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCCC, XNCR, TYRA, and VIR Company Descriptions

C4 Therapeutics NASDAQ:CCCC

Tyra Biosciences NASDAQ:TYRA

Vir Biotechnology NASDAQ:VIR

Xencor NASDAQ:XNCR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools